Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | USP28 | Q96RU2 | 9/20 | 0.45 |
| ▸ | USP25 | Q9UHP3 | 9/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256670 | 0.84 | MTOR (0.49) | MTORMAPTALDH1A1USP28USP25 | |
| SCHEMBL24256673 | 0.83 | MTOR (0.59) | MTORNAMPTMAPTLMNAGAA | |
| SCHEMBL24256847 | 0.80 | USP25 (0.69) | MTORUSP28USP25 | |
| SCHEMBL24256709 | 0.79 | MTOR (0.61) | MTORNAMPTMAPTLMNAGAA | |
| SCHEMBL24256612 | 0.78 | MTOR (0.60) | MTORNAMPTMAPTLMNAGAA | |
| SCHEMBL24256707 | 0.73 | MTOR (0.58) | MTORNAMPTMAPTLMNAGAA | |
| SCHEMBL24256858 | 0.70 | MTOR (0.63) | MTORNAMPTMAPTLMNAGAA | |
| SCHEMBL24256669 | 0.70 | MTOR (0.48) | MTORNAMPTMAPTLMNAGAA | |
| SCHEMBL22644967 | 0.70 | NAMPT (0.56) | MTORNAMPTMAPTLMNAGAA | |
| SCHEMBL24256678 | 0.69 | LMNA (0.67) | MTORNAMPTMAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022035806-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | MTOR 2191/4885NAMPT 2527/4885MAPT 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.